The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of DNA methylation status on first-line antiepidermal growth factor receptor treatment in patients with metastatic colorectal cancer.
 
Hiroki Osumi
No Relationships to Disclose
 
Kota Ouchi
No Relationships to Disclose
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Shin Takahashi
Honoraria - Asahi Kasei; Bayer; Chugai Pharma; Daiichi Sankyo; Japan Blood Products Organization; Medicon; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Merck Serono; Ono Pharmaceutical
 
Akira Ooki
No Relationships to Disclose
 
Keitaro Shimozaki
No Relationships to Disclose
 
Izuma Nakayama
No Relationships to Disclose
 
Takeru Wakatsuki
No Relationships to Disclose
 
Mariko Ogura
No Relationships to Disclose
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Keisho Chin
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Chikashi Ishioka
Honoraria - Asahi Kasei; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin International; Lilly Japan; Nihonkayaku; Ono Pharmaceutical; Otsuka; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Research Funding - Asahi Kasei (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan; Nihonkayaku (Inst); Ono Pharmaceutical (Inst); Otsuka; Sanofi; Shionogi; Taiho Pharmaceutical (Inst); Takeda (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)